Crestor(statin)真神，HSCRP大於2.0但LDL小於130可做為primary CV prevention?
Rosuvastatin Associated with Lower Incidence of Cardiovascular Events in Older Adults
Rosuvastatin is associated with cardiovascular risk reduction in adults aged 70 and older, according to a subanalysis of the industry-funded JUPITER trial published in the Annals of Internal Medicine.
In JUPITER, adults with elevated high-sensitivity C-reactive protein levels and LDL cholesterol levels less than 130 mg/dL were randomized to receive either daily rosuvastatin or placebo. This subanalysis focuses on 5700 adults aged 70 and over.
After a median 2 years' follow-up, the rosuvastatin group had a significant reduction in the occurrence of a first cardiovascular event (stroke, myocardial infarction, unstable angina, revascularization, or cardiovascular death), compared with placebo (1.22 vs. 1.99 events per 100 person-years). Participants aged 70 and over had a greater reduction in absolute risk than their younger counterparts, and the benefit was observed soon after treatment began.
The authors note that, since JUPITER was stopped early, long-term effects could not be determined.
LINK(S):
Annals of Internal Medicine article (Free abstract; full text requires subscription)
Annals of Internal Medicine editorial (Subscription required)
Published in Physician's First Watch April 20, 2010
https://docs.google.com/fileview?id=0B278nGJMQBk7ZjhkNDQ1YWMtNTA0ZC00MzQxLTg3NTEtYmU4MWM2YWRjZjY3&hl=zh_TW
Rosuvastatin is associated with cardiovascular risk reduction in adults aged 70 and older, according to a subanalysis of the industry-funded JUPITER trial published in the Annals of Internal Medicine.
In JUPITER, adults with elevated high-sensitivity C-reactive protein levels and LDL cholesterol levels less than 130 mg/dL were randomized to receive either daily rosuvastatin or placebo. This subanalysis focuses on 5700 adults aged 70 and over.
After a median 2 years' follow-up, the rosuvastatin group had a significant reduction in the occurrence of a first cardiovascular event (stroke, myocardial infarction, unstable angina, revascularization, or cardiovascular death), compared with placebo (1.22 vs. 1.99 events per 100 person-years). Participants aged 70 and over had a greater reduction in absolute risk than their younger counterparts, and the benefit was observed soon after treatment began.
The authors note that, since JUPITER was stopped early, long-term effects could not be determined.
LINK(S):
Annals of Internal Medicine article (Free abstract; full text requires subscription)
Annals of Internal Medicine editorial (Subscription required)
Published in Physician's First Watch April 20, 2010
https://docs.google.com/fileview?id=0B278nGJMQBk7ZjhkNDQ1YWMtNTA0ZC00MzQxLTg3NTEtYmU4MWM2YWRjZjY3&hl=zh_TW
留言
張貼留言